Physician profile
William E Mcelmoyle
NPI 1477545598
$2,849.41
in general payments reported to CMS, 2019-2025
30 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $185 · 2021: $156 · 2022: $456 · 2023: $1,117 · 2024: $353 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413.65 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $351.36 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals Lp | $243.93 | 2020-2025 | Farxiga, Fasenra, Airsupra |
| Pfizer INC. | $234.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.12 | 2019-2024 | Jardiance, Synjardy |
| Abbvie INC. | $189.69 | 2021-2024 | |
| Exact Sciences Corporation | $169.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $145.24 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $110.00 | 2020-2023 | Veozah, Myrbetriq |
| Amgen INC. | $95.20 | 2021-2025 | Repatha, Otezla, Otezla |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.68 | 2023 | |
| Merck Sharp & Dohme LLC | $68.91 | 2019-2022 | |
| Amarin Pharma, INC. | $61.99 | 2020-2023 | |
| Bausch Health US, LLC | $57.41 | 2019-2023 | Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $52.03 | 2019-2023 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $41.90 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $30.08 | 2025 | Spravato |
| Sanofi Pasteur INC. | $26.11 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $25.18 | 2023 | Rexulti |
| Inspire Medical Systems, INC. | $24.99 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $23.77 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $23.56 | 2023 | Crysvita |
| Ibsa Pharma INC. | $23.24 | 2020 | |
| Axsome Therapeutics, INC. | $23.13 | 2023 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.46 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.67 | 2025 | |
| Harmony Biosciences LLC | $18.33 | 2025 | |
| Concordia Pharmaceuticals INC. | $18.32 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.96 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcelmoyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.